Načítá se...
Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients()
In multiple sclerosis (MS()) B cell depleting therapy using monoclonal anti-CD20 antibodies, including rituximab (RTX) and ocrelizumab (OCR), effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the antigen presenting capabilities and antigen...
Uloženo v:
| Hlavní autoři: | , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4082756/ https://ncbi.nlm.nih.gov/pubmed/24928997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1400118 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|